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Background: Depression is a debilitating mental health problem that tends to run a chronic, recurrent course. Even
when effectively treated, relapse and recurrence rates remain high. Accordingly, interventions need to focus not
only on symptom reduction, but also on reducing the risk of relapse by targeting depression-related disturbances
that persist into remission. We are addressing this need by investigating the efficacy, acceptability and feasibility
of a MEmory Specificity Training (MEST) programme, which directly targets an enduring cognitive marker of
depression - reduced autobiographical memory specificity. Promising pilot data suggest that training memory
specificity ameliorates this disturbance and reduces depressive symptoms. A larger, controlled trial is now
needed to examine the efficacy of MEST. This trial compares MEST to an education and support (ES) group,
with an embedded mechanism study.
Methods/Design: In a single blind, parallel cluster randomised controlled trial, 60 depressed individuals
meeting diagnostic criteria for a current major depressive episode will be recruited from the community and
clinical services. Using a block randomisation procedure, groups of 5 to 8 participants will receive five weekly
sessions of MEST (n = 30) or education and support (n = 30). Participants will be assessed immediately post-treatment,
and at 3- and 6-months post-treatment (MEST group only for 6-month follow-up). Depressive symptoms at 3-month
follow-up will be the primary outcome. Secondary outcomes will be change in depressive status and memory
specificity at post-treatment and 3-months. The 6-month follow-up of the MEST group will allow us to examine
whether treatment gains are maintained. An explanatory question will examine variables mediating improvement in
depression symptoms post-treatment and at 3-month follow-up.
Discussion: This trial will allow us to investigate the efficacy of MEST, whether treatment gains are maintained, and the
mechanisms of change. Evidence will be gathered regarding whether this treatment is feasible and acceptable as a
low-intensity intervention. If efficacy can be demonstrated, the results will support MEST as a treatment for depression
and provide the foundation for a definitive trial.
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Depression is a pervasive mental health condition that is a
leading cause of disability worldwide [1]. As well as caus-
ing significant distress to the individual and their families,
the burden of disease at the societal level is estimated to
cost the United Kingdom approximately £9 billion each
year [2]. Epidemiological studies have established depres-
sion as a lifelong chronic illness, with more than 80% of
individuals experiencing repeated episodes [3]. Of concern
is that with each successive depressive episode experi-
enced, there is increased risk of future recurrence [4].
Gold standard psychological treatments, such as Cognitive
Behavioural Therapy (CBT), can successfully treat depres-
sive illness. However, only about half of patients receiving
treatment will respond, and, even if they do, the risk of re-
lapse and recurrence remains high [3]. If depressive disor-
ders are to be more effectively treated in the future, a
better understanding of factors that increase the risk of re-
lapse/recurrence is needed. One way to address this need
is to focus on cognitive markers of depression that do not
necessarily remit following treatment.
It is widely accepted that depression is characterised
by a range of disturbances in autobiographical memory.
Specifically, the tendency to recall overgeneral memories
(that is, memories of broader, more general categories of
events rather than memories of a particular discrete in-
stance) has been identified as a stable cognitive marker of
depression [5]. Depressed individuals have difficulty re-
trieving specific memories of past autobiographical events
in response to cue words. For example, in response to the
cue word ‘excited’ there is a tendency to provide sum-
marised categories of similar events (for example, birthday
parties) or details of an event that occurred over a pro-
tracted time period (for example, my holiday to Wales),
rather than a specific event (for example, going to the
Leonard Cohen concert in London last month).
Research over the past two decades has established that
such overgeneral memory recall is reliably associated with
depressive symptoms in both clinical and analogue sam-
ples. Furthermore, overgeneral memory recall is not just a
product of being depressed - following the recovery of a
depressive episode, reduced specificity remains stable.
That is, formerly depressed patients show comparable
levels of generality to their depressed counterparts (for ex-
ample, [6,7]), suggesting that it is a trait vulnerability fac-
tor for future recurrence. In support, longitudinal findings
show that the tendency to recall overgeneral memories
predicts the course of depression prospectively (for ex-
ample, [8-11]). Furthermore, overgeneral memory recall is
associated with negative psychological outcomes that ex-
acerbate depression including impaired problem solving
ability [12], difficulty in imagining future events [13],
heightened rumination [14] and executive dysfunction
[15]. Therefore, this relative imbalance in the specificityof recalled autobiographical events is a key driver of
depressive illness.
Theoretical accounts originally conceptualised overge-
nerality as a mode of memory retrieval that develops in an
attempt to minimise the potential for negative emotion ex-
perience that arises from the recall of specific distressing
memories [14]. This avoidance conceptualisation has since
been elaborated upon, with proponents of the CaR-FA-X
model (that is, capture and rumination, functional avoid-
ance, impaired executive control) suggesting that a num-
ber of processes, either alone or in combination, account
for the tendency to retrieve overgeneral memories among
depressed individuals. Specifically, Williams and colleagues
[5] suggest that three mechanisms underlie overgeneral
memory: capture and rumination, functional avoidance and
impaired executive control (for recent review, see [16]). A
comprehensive analysis of this model is beyond the scope
of this protocol, but in short, the capture and rumination
mechanism relates to the possibility that overgeneral mem-
ory is facilitated by mnemonic information, which activates
ruminative processes during memory retrieval. In support,
studies have found that experimentally induced ruminative
processing leads to overgeneral memory recall while non-
ruminative thinking does not [17-20]. The second factor,
functional avoidance, is similar to the initial conceptualisa-
tion of overgeneral memory as an avoidance mechanism,
whereby remembering autobiographical events overgener-
ally has been suggested to reduce the affective impact of
emotional memories. Consistent with this proposal are
findings showing that avoiding specific recall immediately
following an aversive experience reduces emotional distress
[21]. Third, the model asserts that impaired executive con-
trol limits the ability of an individual to remain focused on
retrieving a specific memory. To support this, numerous
studies have found that overgeneral memory recall is asso-
ciated with impaired executive control on a range of out-
comes including verbal, spatial, and memory measures [15].
While empirical evidence is consistent with the three pro-
cesses identified in the model, on-going research in the area
is needed to more fully elucidate the mechanisms and inter-
actions underlying overgeneral memory recall.
From a clinical perspective, the reliable and robust rela-
tionship between overgenerality and adverse psychological
phenomena make reduced memory specificity an attract-
ive target for therapeutic change. Moreover, research sug-
gests that overgeneral memory recall is not a fixed feature
of an individual’s mnemonic style [22] and can be modified
[23]. As derived from the existing framework, it follows that
enhancing access to specific memories should yield thera-
peutic benefit. This elegantly simple premise was first
empirically addressed by Raes, Williams and Hermans
[24], who developed a brief MEmory-Specificity Training
(MEST) procedure. The programme was designed as a
four-session, group training program whereby participants
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response to different cue words. In this pilot study of 10
depressed female inpatients, results showed that memory
specificity improved following the training, along with im-
provements in symptoms and depression-related processes
(for example, rumination, problem-solving and cognitive
avoidance). While promising, this first pilot included a
small sample size, no control condition, and no follow-up.
Having established that in principle, memory specificity
can be trained using this programme, it was followed up
with a randomised clinical trial comparing MEST to a
non-active control condition in a group of bereaved, de-
pressed Afghani teenage refugees living in Iran [25]. Con-
sistent with the earlier pilot study [24], training improved
specificity levels in the MEST group. Symptom measures
at post-training indicated that there was no group differ-
ence in depressive symptoms. However, participants who
received MEST had significantly lower symptom levels
than those in the control group at 2-month follow-up, and
they were no longer in the clinical range. Finally, this im-
provement in depression in the MEST group was medi-
ated by improvements in memory specificity from the
beginning to the end of training.
The data from these two studies are encouraging - they
suggest that MEST may improve outcomes in depression,
once shifts in memory specificity have had time to gain
traction in day-to-day cognitive processing. Similar en-
couraging data are also emerging from the post-traumatic
stress disorder (PTSD) literature [26]. It is now time for
the next stage of the treatment development process.
Medical Research Council (MRC) guidelines [27] for the
development of complex interventions specify that once
the necessary pre-clinical and pilot research foundations
have been completed, a Phase II exploratory trial to evalu-
ate the efficacy, feasibility and acceptability of an interven-
tion is needed. We are addressing this need by conducting
a randomised controlled clinical trial in which MEST is
compared to an appropriate, active control group.
If MEST is established as efficacious, acceptable to pa-
tients, and feasible to deliver, it would confer a number
of advantages. First, it is a relatively brief and thus cost-
effective intervention that may be suitable as an adjunct to
more comprehensive therapies or as a standalone, low-
intensity intervention for mild forms of depression. More-
over, it can be delivered by individuals with limited training
and experience, and, as it does not involve addressing emo-
tional difficulties, lends itself to implementation in challen-
ging clinical contexts by individuals who do not necessary
have the training in how to manage sensitive issues that
arise in clinical groups. This is particularly important in
countries with fewer mental-health resources [28]. From a
public health perspective, this treatment is very much in
line with UK government initiatives aiming to deliver more
accessible, cost-effective psychosocial interventions, suchas the Improving Access to Psychological Therapies (IAPT)
programme [29]. Another advantage associated with
MEST is that it targets a cognitive marker of depression
that does not necessarily improve as an individual comes
out of a depressive episode (for example, [8,30]). This pro-
vides reason to expect that this intervention may reduce
future relapse and recurrence via its impact on specificity-
related processes.
A key question that remains unanswered is exactly how
MEST works. It is hypothesised that MEST training
changes processes believed to mediate the impact of the
mode of memory retrieval on depression, namely, by de-
creasing cognitive avoidance, reducing rumination, improv-
ing problem solving, and improving executive control.
However, the degree to which changes in these variables is
mediated by changes in memory specificity is unknown. An
embedded mechanism study will allow investigation of the
processes mediating change.
In summary, there is promising evidence suggesting
that MEST offers a novel way through which a key
memory disturbance linked to depression and adverse
psychological sequelae may be targeted. In this cluster
RCT we will compare MEST to an active education and
support (ES) intervention control condition in a sample
of depressed British adults. This trial was designed to
answer four key questions. First, does MEST improve
specificity and reduce depression? Second, are gains
maintained over the longer term? Third, is MEST su-
perior to an education and support intervention in its ef-
fects on depression and specificity? Fourth, what are the
mechanisms mediating any treatment effects?
Methods/Design
Study design
The design is a single-blind, parallel cluster RCTcomparing
MEST to an ES intervention, with an embedded mechan-
ism study. The intervention duration is equivalent in both
conditions and participants will be assessed four times - at
baseline, at post-treatment, and at 3-month and 6-month
follow-up time points. The first three assessment points
(that is, baseline, post, and 3-month follow-up) are face-to-
face and include the full battery of assessment measures,
including primary and secondary outcomes and process
measures. Assessment at 6 months will be for the MEST
group only and will take place via phone. This final as-
sessment includes primary and secondary outcomes
only (with the exception of the Autobiographical Mem-
ory Test; AMT).
Participants and recruitment
A total of sixty individuals aged 18 to 65 with a principle
diagnosis of major depressive disorder (recurrent episode)
will be randomised to either MEST (n = 30) or ES (n = 30).
Inclusion criteria are a diagnosis of major depressive
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of a current major depressive episode; the presence of
moderate symptoms defined as a Beck Depression Inven-
tory (BDI-II) [31] score of >13, and memory specificity of
less than 0.70, as assessed on the AMT [32]. Participants
need to have a baseline level of specificity of less than 0.70
to be invited into the trial because a higher level illustrates
that memory specificity is not a difficulty for that individ-
ual, and there will be minimal opportunity for specificity-
related benefits to accrue. Participants continue with their
usual treatment (for example, antidepressant medication
or psychological therapy) during the trial. Exclusion
criteria are: high levels of suicidality or harm to others
(assessed via interview and exclusion according to clin-
ical judgement), a secondary diagnosis of another
affective disorder or a psychotic disorder; current drug/
alcohol abuse or dependence all assessed via the Struc-
tured Clinical Interview for the Diagnostics and Statis-
tics Manual – SCID-V, [33]; a diagnosed Axis II
disorder (assessed via participant report); and the pres-
ence of head trauma or organic brain damage (assessed
via participant report).
There are three pathways through which participants
will be recruited. The first is directly from the community
via posters and advertisements around the Cambridge
(UK) area. The second is from our departmental volunteer
panel comprising individuals with a history of depres-
sion who have previously participated in our research.
The third will be via clinical services offered within the
Cambridgeshire and Peterborough Foundation Trust. Pa-
tients in these services will be identified by members of
the clinical team and provided information about the trial.
They will be able to opt in by contacting us directly.
Participants who have previously been assessed by our
research team will be notified about the study by email.
Participants who have not previously volunteered in our
research (that is, community members and patients in
clinical services) who express interest will be provided
written information about the study (via email or post)
after contacting us. After reading the study information
sheet, interested participants will be administered a brief
phone screen (using items from the Mood Module of
the SCID-IV) to verify whether they meet criteria for a
current major depressive episode. Those who do will
then be invited to attend a session at the Medical Re-
search Council Cognition and Brian Sciences Unit for a
full baseline assessment involving clinical interviews and
experimental tasks, as outlined below.
Participant allocation
Eligible participants will be cluster randomised using a
blocked randomisation procedure with 5 to 8 participants
in a group to receive the intervention. This will be achieved
using computer-generated, quasi-random numbers and willbe conducted by the trial statistician (Watson), blind to
study objectives. Once generated, this information is
passed to the trial lead (Dalgleish), who informs the pro-
ject coordinator responsible for delivering the intervention
(Werner-Seidler) within 48-hours of the commencement
of a given group.
Figure 1 summarises the trial CONSORT (consoli-
dated standards for reporting trials) diagram. Following
randomisation, patients are offered treatment for five
consecutive weeks (commencing within four weeks of
the baseline assessment).
Interventions
MEmory Specificity Training
MEST is the training package developed by Raes and col-
leagues, used in the first pilot study of memory specificity
training [24]. For the current study, the original treatment
manual was translated from Dutch into English, and, in col-
laboration with the treatment developer, has been extended
from four to five sessions, as used in our pilot RCT [25]. It
consists of a fully manualised, structured treatment deliv-
ered over five 60-minute sessions to groups of 5 to 8 indi-
viduals. The treatment aims to enhance memory specificity
through the systematic practice of memory retrieval in re-
sponse to emotional and neutral cue words. This practice
takes place both during the sessions and at home.
The first session involves providing basic psycho-
education about depressive symptoms and memory diffi-
culties common in depression. As a group, participants
then practice recalling memories in response to positive
and neutral cues, with demonstrations and support from
the therapists. For homework, participants have to identify
specific memories in response to ten cue words, and iden-
tify an additional ‘memory of the day’ each day. The second
session follows the same format with further practice. For
homework, participants must identify specific memories in
response to ten cue words, and identify two further daily
specific memories. In the third session, practice in response
to negative cues (as well as positive cues) is introduced, and
homework is identical to that following Session 2. Session 4
involves practice to positive, negative, and neutral cues and
also includes an example of noticing overgeneral thinking
in everyday contexts. For homework, participants identify
memories in response to ten cues, identify a single ‘memory
of the day’ each day, and provide a daily example of when
they have noticed themselves thinking in an overgeneral
fashion. The final session involves further practice and revi-
sion of the material covered throughout the treatment.
Education and support
The ES intervention will follow the same format and
length as the MEST intervention (that is, delivered to
groups of 5 to 8 individuals over five 60-minute sessions).
ES has been manualised for this trial and is a cognitively-
Allocated to Support
n = 
Allocated to MEST
n =
MEST trial
Assessed Post-Support 
n =
Assessed Post-MEST
n = 
3-month follow up 
Randomised
N = 
6-month follow up 
Baseline Assessment:
N = 
Assessed for eligibility
N = 
3-month follow up 
Figure 1 CONSORT diagram.
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judgemental, supportive environment in which participants
are encouraged to raise and discuss a range of events that
occur each week. These events may be positive, negative, or
benign and non-emotional in nature: it is up the individuals
to bring to the group whatever they would like. Through
reflection and discussion, the goal is to support and help in-
dividuals attain optimal adjustment and to better cope with
everyday life. This approach draws on the supportive as-
pects of the therapeutic relationship to assist with more ef-
fective psychological functioning, with input from other
group members. It is a non-directive intervention whereby
therapists do not use directive methods such as cognitive-
behavioural techniques (for example, Socratic questioning,
cognitive restructuring, behavioural experimentation).The rationale for choosing an education and support
comparison group over more traditional psychological
approaches (for example, supportive counselling, CBT)
was to ensure that the content covered by the two in-
terventions is as similar as possible. More traditional
approaches tend to focus on distressing and emo-
tional material, which is not the focus of the MEST
intervention. Therefore, to optimise equivalence in
content between the groups we decided to take a cog-
nitive approach and ask people to record material
from each week that can be positive, negative or neu-
tral. The role of the group is to then help individuals
to notice patterns in their responses and adopt a self-
reflective approach, which may improve psychological
functioning.
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symptoms is presented and the experience of group mem-
bers is normalised. Participants are invited to share why
they have decided to participate in this study. An outline of
the programme is then provided and participants are in-
formed about how to complete the homework daily diary
where they note down a significant event that occurred
each day, which can be shared in the following session. The
second session involves reviewing the homework and con-
tinued discussion of events that participants have noted
down in their diaries. These discussions are led by the ther-
apists, but as with the MEST intervention, input from other
group members is encouraged. Sessions 3, 4, and 5, follow
an identical structure - a homework review, followed by
discussion and support, with the homework task to record
a positive, negative or neutral daily event for discussion at
the next session. The final session does not require comple-
tion of homework tasks. The ES manual was developed by
two clinical psychologists (Werner-Seidler and Dalgleish),
in consultation with two experienced counsellors from the
Cambridge area.
Treatment integrity
Two clinical psychologists with experience in treating adult
depression will deliver the MEST and ES interventions.
Treatment fidelity and clinician adherence will be estab-
lished using continued monitoring and through independ-
ent rating. After every session, clinicians will complete the
Treatment Fidelity Checklist, which is a session-by-session
measure of compliance with the protocol, and these will be
evaluated during weekly clinical supervision with the trial
lead. In addition, a random 25% of the audio-taped treat-
ment sessions will be rated for adherence to the manuals
by an experienced clinician, independent of the core trial
team. Homework completion will be monitored and
assessed using self-report questionnaire measures.
Measures
Primary outcomes
The primary outcome measure will be depressive symp-
toms at 3-month follow-up using the well-established,
psychometrically sound self-report measure, the Beck
Depression Inventory II (BDI-II) [31].
Secondary outcomes
Secondary outcomes will be depressive diagnostic status
and depression-free days since the beginning of treatment
at the post, 3-month and 6-month (MEST group only)
follow-up assessment as measured by the Longitudinal
Interval Follow-up Evaluation (a form of the Structured
Clinical Interview for DSM-V, which is the gold standard
for diagnostic assessment) [33]; depressive symptoms at
post-treatment and 6-month follow-up (as measured by
the BDI-II); and memory specificity at post and 3-monthfollow-up, as measured by the gold standard in memory
specificity research, the AMT [32].
Process measures
To address our explanatory question concerning the mech-
anisms by which MEST improves outcomes in depression,
we include a number of process-related tasks, parallel
forms of which will be administered at baseline, at post-
intervention, and at 3-month follow-up, across the trial
arms. Accordingly, change on theoretically-derived pro-
cesses from pre- to post-treatment (outlined below) will be
used to predict treatment outcome at follow-up using me-
diational analyses [34]. Derived from theory and evidence,
we will examine whether the effect of MEST on treatment
outcome is mediated by changes in memory specificity,
interpersonal problem solving, rumination, cognitive avoid-
ance, and executive control. Problem-solving will be mea-
sured using a shortened version of the Means-Ends
Problem Solving task [35], which has been used previously
in clinical research. Rumination and cognitive avoidance
will be measured using the psychometrically valid gold-
standard self-report measures for each construct - the
Rumination Response Scale (RRS) [36] and the Cognitive
Avoidance Questionnaire [37]. Executive control will be
indexed via verbal fluency and working memory measures
commonly used in neuropsychological assessment [38].
Methodological aspects
Power analysis and sample size
Although a standard power calculation based on detecting
treatment effects would be the conventional approach to
determining sample sizes for clinical trials, the main aim of
the current exploratory trial is to investigate the efficacy, ac-
ceptability and feasibility of MEST, in preparation for scaled
up later phase evaluations of the intervention in line with
MRC guidance. Our previous experience with Phase II ex-
ploratory trial platforms indicates that 60 participants (30
in each arm) will provide sufficient numbers to evaluate
outcome, feasibility and acceptability, and to generate pre-
liminary process data for this treatment. This sample size
will give 24 patients in each arm if we allow for 20% attri-
tion. This will provide a plausible range of point estimates
of effect on our set of outcome measures sufficient to guide
us in sample size calculations for later phase trial work.
Data collection
Outcome data will be collected on site at three assessment
points (baseline, post-treatment, and 3-month follow-up).
Outcome data on all participants who are randomised will
be collected if possible and with appropriate consent. At
6-month follow-up, participants from the MEST arm will
be contacted by phone and administered the Longitudinal
Interval Follow-Up Evaluation to ascertain depression-free
days (a form of the SCID-IV), and will be asked to
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and the full process battery will not be administered at
the 6-month follow-up. Data will be stored securely at
this site under the management of the trial coordinator
(Werner-Seidler). Spot checks on data entry will be per-
formed to promote data quality.
Blinding
Outcome assessments are conducted by independent raters
who have no therapeutic relationship with the patients and
are blind to treatment condition. Double blinding of pa-
tients and therapists is not possible due to the nature of the
trial (that is, a psychological intervention). Under no cir-
cumstance will unblinding be necessary since participants
and therapists are not blinded to intervention allocation.
Statistical analysis plan
Initial analyses of the primary and secondary outcomes will
be conducted by the trial statistician, following CONSORT
standards (there are no planned interim analyses). Multiple
imputation will be used to handle missing data. Initial ana-
lyses will be conducted on an intention-to-treat basis, with
subsequent analyses being per protocol. Mixed model ana-
lyses of variance (ANOVAs) will be used to compare
groups at the four assessment points - baseline, post-
intervention, 3-month follow-up, and 6-month follow-up
on primary and secondary outcomes, as appropriate. Base-
line levels on relevant measures will be included as covari-
ates, as appropriate. Mediational analyses following the
Kraemer recommendations [34] will investigate hypothe-
sised mechanisms of change across the trial arms.
Monitoring and data management
The trial will take place at the Medical Research Council’s
Cognition and Brain Sciences Unit in Cambridge, England.
As a Phase II trial, a data-management committee was
considered unnecessary and the trial team is therefore re-
sponsible for monitoring and data management. Data will
be monitored for completeness, consistency, and plausibil-
ity using spot checks and plausibility checks carried out by
the trial statistician. The trial lead (Dalgleish), statistician
(Watson) and coordinator (Werner-Seidler) will have full ac-
cess to the final trial dataset. The study data will be reported
in line with the current CONSORT recommendations [39].
Safety aspects
Adverse events refer to unwanted medical events (for
example, worsening symptoms) occurring throughout
the trial, regardless of whether they are causally related
to the trial procedures. Adverse events are managed in line
with UK MRC protocols, and in the unlikely case of an ad-
verse event, it will be documented appropriately. Precautions
have been taken to reduce the likelihood of adverse events
occurring; for example, patients who are acutely suicidal orat high risk of harm do not meet study inclusion criteria.
The interventions are delivered by clinical psychologists ex-
perienced in the management of risk and in the treatment
of chronic, recurrent, and severe depression. In the case of
any adverse events, participation in the trial will be discon-
tinued. The trial is underwritten by the UK MRC in case
any individual suffers harm or requires post-trial care.
Ethical approval and protocol amendments
This project has received ethical approval from the UK
National Research Ethics Committee (East of England, 11/
H0305/1). The study will be conducted within appropriate
UK MRC, National Health Service and professional ethical
guidelines, ensuring that Good Clinical Practice proce-
dures are adhered to at all times. Protocol amendments
will be circulated to the ethics, research and development,
and trial team. Relevant adjustments will be made to any
published protocol.
Confidentiality
All participants will give written informed consent prior
to being assessed for eligibility of the study. To maintain
confidentiality, all participants are given a trial number
so that personally identifying information is not linked
to assessment or trial information.
Dissemination policy
There are no publication restrictions, and findings will
be disseminated broadly to participants, healthcare pro-
fessionals, the public, and other relevant groups.
Discussion
According to the World Health Organisation [1], depres-
sion is major global burden of disease and, by 2020, will be
the second leading cause of world disability. Depression af-
fects people in all communities across the world, making it
a matter of global concern from health, social and eco-
nomic perspectives. Fortunately, evidence-based treatments
that work such as cognitive-behavioural therapies are avail-
able. However, these treatments are not always accessible to
those who need them, and the treatments themselves are
expensive to deliver. There has been a growing recognition
of the need to develop cost-effective interventions that can
be delivered in a stepped care model, supported by a num-
ber of government initiatives (particularly in the UK). The
underlying goal is to make evidence-based interven-
tions more accessible and affordable (for example, NHS
internet-based CBT, IAPT). The proposed RCT is in
line with this objective.
The two pilot trials that have been conducted suggest
that MEST, if efficacious in the treatment of depression,
may offer a cost-effective, brief, low-intensity intervention
with potential for cross-cultural application. For example,
one of the pilot studies was conducted with Afghan
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Belgium. This is of particular interest given that risk factors
for depression include economic and social disadvantage
[40] and those in impoverished communities have greater
difficulty accessing health care [41]. If acceptability, feasibil-
ity, and superiority to the ES control can be demonstrated,
the results from this trial will support the need for a fully
powered Phase III definitive trial to examine MEST as a
treatment for mild to moderately depressed individuals. We
anticipate that MEST may be used as an adjunct or precur-
sor to more comprehensive therapies such as CBT. It is
possible that MEST may have utility in reducing symptoms
to a level where patients are able to engage in more de-
manding therapies such as CBT. Results of this trial will
also indicate whether there is potential for MEST to be
used as a stand-alone treatment for depression. Further, we
expect that the idiosyncratic nature of MEST may appeal to
particular patient groups who do not wish to address emo-
tional content. Finally, the embedded process study will en-
able us to better understand the mechanisms driving the
therapeutic effects of the treatment.
Trial status
Recruitment commenced in January 2014.
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